Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast 2024-2033

Overview and Scope
Chemotherapy induced peripheral neuropathy (CIPN) refers to a set of symptoms and complications that can develop because of certain chemotherapy drugs used in the treatment of cancer. It is a type of peripheral neuropathy, which involves damage or dysfunction of the peripheral nerves that connect the brain and spinal cord to the rest of the body.

Sizing and Forecast
The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.54 billion in 2023 to $1.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to chemotherapy advancements, cancer treatment expansion, limited treatment options, increased cancer incidences, neurological research.

The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to targeted therapies development, neuroprotective agents, integrated care pathways, patient-centered care models, regulatory support. Major trends in the forecast period include novel drug formulations, non-pharmacological interventions, neuroplasticity-based therapies, long-term survivorship support, cognitive behavioral therapies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Segmentation & Regional Insights
The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented –

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2023. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=11967&type=smp

Major Driver Impacting Market Growth
The increasing prevalence of cancer is expected to propel the growth of the chemotherapy-induced peripheral neuropathy treatment market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Chemotherapy-induced peripheral neuropathy is a potential side effect of certain chemotherapy drugs used in the treatment of cancer. The chemotherapy-induced peripheral neuropathy treatment market is subjected to grow as there is a rise of cancer cases globally. For instance, in January 2023, according to the report published by the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the increasing prevalence of cancers driving the growth of the chemotherapy-induced peripheral neuropathy treatment market.

Key Industry Players

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market report are Sanofi SA, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical Company, Amgen Inc., Asahi Kasei Pharma Corporation, Toray Industries, Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., BioMérieux SA, Jazz Pharmaceuticals Inc., WEX Pharmaceuticals Inc., Quidel Corporation, Laboratories Dr. Esteve S.A. (ESTEVE), Genentech Inc., MediciNova Inc., ChromaDex Corp, WinSanTor Inc., Solasia Pharma K.K., NeuroMetrix Inc., Nemus Bioscience Inc., Aphios Corporation, Kineta Inc., DARA BioSciences Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Krenitsky Pharmaceuticals Inc.

The chemotherapy induced peripheral neuropathy treatment market report table of contents includes:

1. Executive Summary
2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics
3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies
4. Chemotherapy Induced Peripheral Neuropathy Treatment Market – Macro Economic Scenario
5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth
.
.
.
31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Other Major And Innovative Companies
32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Benchmarking
33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market
35. Chemotherapy Induced Peripheral Neuropathy Treatment Market Future Outlook and Potential Analysis

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model